Stifel Nicolaus Reaffirms Their Buy Rating on Immunic (IMUX)

Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter

According to TipRanks, Matteis is a 5-star analyst with an average return of 13.8% and a 51.32% success rate. Matteis covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals, BioMarin Pharmaceutical, and Contineum Therapeutics, Inc. Class A.

Immunic has an analyst consensus of Strong Buy, with a price target consensus of $36.50.

Based on Immunic’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $32.59 million. In comparison, last year the company had a GAAP net loss of $25.47 million